News

The randomized double-blind, placebo and positive controlled trial involving approximately 120 adult female women began in early March 2009 with data expected in approximately 60 days. In an

In June 2006 Questcor submitted a supplemental new drug application (sNDA) to the FDA and in May 2007 the FDA determined the sNDA was not approvable in the

AR-42 is an orally available, novel, potent, small molecule that modifies the acetylation of histones and other molecules, and is a targeted inhibitor of the Pan-DAC and Akt

Gross profit from continuing operations was $3.4 million or 55% during the fourth quarter of 2008 compared to $3.9 million or 60% during the comparable period of 2007.

According to Lifeline Biotechnologies, OvaScope has been designed and developed to assist in the early detection of ovarian cancer. To date, the preliminary testing has proved to be

Once the abbreviated new drug application (ANDA) is approved by FDA, Global Pharmaceuticals, Impax’s generic division, will commercialize the products. Doryx is a tetracycline-class antibacterial indicated for rickettsial

Specifically, SF2626 has demonstrated the ability to inhibit both Phosphoinositide-3-kinase (PI3K) and MEK, the key component of the RAS/RAF/MEK/ERK pathway. Both PI3K and MEK are frequently activated in

AequoScreen will be used by Sangmyung University as part of its efforts to establish an academic G-protein coupled receptor (GPCR) screening facility together with the Korea Chemical Bank,

The company had applied for the reissue patent in January 2007, in order to correct a technical defect in the ‘995 enantiomer patent for atorvastatin calcium, the salt